Axion BioSystems Acquires High-Throughput High-Density CMOS MEA Technology From CytoTronics

Axion BioSystems Acquires High-Throughput High-Density CMOS MEA Technology From CytoTronics

https://www.bioprocessonline.com/doc/axion-biosystems-acquires-high-throughput-high-density-cmos-mea-technology-from-cytotronics-0001

Publish Date: 2026-02-04 15:27:00

Source Domain: www.bioprocessonline.com

Next-generation CMOS MEA chip technology acquired by Axion BioSystems integrates over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput, single-cell–level functional screening for disease research and drug discovery.

Atlanta – Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc. The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug discovery.

Bioelectronic assays use biocompatible electronic microsensors embedded in the cell culture surface to continuously monitor living cells, detecting cell number, morphology, and even neural firing and cardiac beating without additional labels or dyes.

CytoTronics’ next-generation CMOS (Complementary Metal–Oxide–Semiconductor) microelectrode array (MEA) plates contain over 13 million nanoscale multimodal electrode-based sensors distributed across industry-standard 96- or 384-well microplates, enabling high-throughput screening for drug discovery at unprecedented single-cell resolution.

Co-founder and former Chief Executive Officer of CytoTronics, Inc., Jeffrey Abbott, PhD, now Vice President at Axion BioSystems, said: “Axion has a long-standing reputation for delivering intuitive, reliable, and scalable electrophysiology platforms to the cell biology community. That industry leadership makes Axion the ideal home for CytoTronics’ innovative technology. I’m excited to work with the Axion team to commercialize the next generation of high-throughput, high-density CMOS MEA assays for neural and cardiac drug discovery.”

“Since its…

Source